RCT | Early treatment with Molnupiravir did not reduce hospitalizations in high-risk adults with COVID-19

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial – The Lancet

Commentaries: 

Molnupiravir does not reduce COVID-19 hospitalisations or deaths in vaccinated, high risk people – National Institute for Health and Care Research

Molnupiravir doesn’t cut Omicron hospitalization, death but can speed recovery – CIDRAP